Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China ...Middle East

- Robust HbA1c reduction of 2.4% was observed with 1.2 mg XW003 dose - Up to 88% of participants achieved HbA1c ≤ 7% and up to 72% achieved HbA1c ≤ 6.5% at the end of the 20-week treatment - XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly reported...

Hence then, the article about sciwind biosciences announces positive topline results from 20 week phase 2 clinical trial of xw003 ecnoglutide a novel long lasting glp 1 analogue in adult patients with type 2 diabetes in china was published today ( Wednesday 03/08/2022 - 03:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China )

Also on site :

• Hollywood mourns loss of beloved makeup artist Jasen Kaplan
• Suspected mountain lion attack in Colorado mountains under investigation
• Rose Parade Viewers 'Floored' by 'Disaster' Finale Performance: 'Yikes'